911418-33-2

Basic information

• Product Name: tert-butyl 5-(6-acetoxy-2-(3-nitrophenyl)quinazolin-4-ylamino)-1H-indazole-1-carboxylate
• Synonyms: tert-butyl 5-(6-acetoxy-2-(3-nitrophenyl)quinazolin-4-ylamino)-1H-indazole-1-carboxylate
• CAS NO: 911418-33-2
• Molecular Weight: 540.535
• Mol File: 911418-33-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: tert-butyl 5-(6-acetoxy-2-(3-nitrophenyl)quinazolin-4-ylamino)-1H-indazole-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 5-(6-acetoxy-2-(3-nitrophenyl)quinazolin-4-ylamino)-1H-indazole-1-carboxylate(911418-33-2)
• EPA Substance Registry System: tert-butyl 5-(6-acetoxy-2-(3-nitrophenyl)quinazolin-4-ylamino)-1H-indazole-1-carboxylate(911418-33-2)

Safety Data

• Hazardous Substances Data: 911418-33-2(Hazardous Substances Data)

Upstream product

• 129488-10-4 5-Amino-indazole-1-carboxylic acid tert-butyl ester 
• 911418-32-1 4-chloro-2-(3-nitrophenyl)quinazolin-6-yl acetate 
• 1882-71-9 2-amino-5-methoxybenzamide 
• 63932-00-3 5-methoxy-2-nitrobenzoyl chloride 
• 41994-92-7 2-nitro-5-methoxybenzamide 
• 1882-69-5 5-methoxy-2-nitro-benzoic acid 
• 911418-30-9 5-methoxy-2-(3-nitrobenzoylamino)benzamide 
• 911418-31-0 6-methoxy-2-(3-nitrophenyl)quinazolin-4(3H)-one 
• 371947-63-6 2-(3-nitrophenyl)-4-oxo-3,4-dihydroquinazolin-6-yl acetate 
• 371946-32-6 6-hydroxy-2-(3-nitrophenyl)quinazolin-4(3H)-one 

Downstream Products

• 911418-39-8 tert-butyl 5-(2-(3-butyramidophenyl)-6-hydroxyquinazolin-4-ylamino)-1H-indazole-1-carboxylate 
• 911418-36-5 tert-butyl 5-(6-hydroxy-2-(3-(nicotinamido)phenyl)quinazolin-4-ylamino)-1H-indazole-1-carboxylate 
• 911418-90-1 tert-butyl 5-(2-(3-butyramidophenyl)-6-(2-chloroethoxy)-quinazolin-4-ylamino)-1H-indazole-1-carboxylate 
• 911418-35-4 tert-butyl 5-(6-acetoxy-2-(3-(nicotinamido)phenyl)quinazolin-4-ylamino)-1H-indazole-1-carboxylate 

Relevant articles and documents

RHO KINASE INHIBITORS

The present invention relates to inhibitors of ROCK1 and ROCK2, which may be selective for ROCK2, and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and/or ROCK2. Also provided are treatments combining inhibitors of ROCK1 and/or ROCK2 with statins.

PHARMACOKINETICALLY IMPROVED COMPOUNDS

The present invention relates to inhibitors of ROCKl and R0CK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCKl and or R0CK2 that are useful for the treatment of disease.